Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Anastasia Amoroso, Chief investment strategist, iCapital and Rob Sechan, Managing Partner, New Edge Capital commented about whether WFC-N, XLI-N, MMM-N, ADBE-Q, HD-N, APO-N, IJR-N, XHB-N are stocks to buy or sell.

BUY

M&A activity was turning around even before the election with $2 trillion of deals this year that exceeds that of 2021. Looking forward is the perfect environment for M&A. Upside to come.

BUY

They report tomorrow. Lower interest rates will push sales, and the extreme weather is behind us.

BUY ON WEAKNESS

A tough stock that you must be patient with, but ultimately this is a double-digit compounder with healthy fundamentals. They're seeing slower than expectation monetization of AI (Firefly). It's a show-me story. He's underwater on this, but you can buy this at current levels.

BUY

It's a turnaround story, so he initiated a position. He is selective in industrials, because they trade at a 24x forward PE, higher than the S&P.

HOLD

Industrials have done very well for him, but are now expensive at 24x forward PE, higher than the S&P. Industrials are cyclical, too.

BUY

He's overweight financials, which benefit from a soft landing, steeper yield curve which drives their net interest income higher. WFC has managed expenses very well. There's more bang for you buck here vs. its peers.

BUY

He hates to say this, but the world will remain a violent place. 

PARTIAL BUY

A definite hold, though you can probably add to it here. It reports Thursday and he wants to hear how the streaming business is going, and are the theme parks recovering. A lot of things 

BUY

It reports tomorrow. It's a pricey stock, but it's also growing like a weed. People love their shoes. Volumes are up.

BUY

A very cyclical company in construction materials. Lower interest rates should help the flagging housing industry. Benefits from infrastructure spending and have reported good numbers recently.

BUY ON WEAKNESS

He added more AbbVie. Obviously, today's news about the disappointing drug trials is not good. This schizophrenia drug was projected to make $1.1 billion in sales four years from now. But today's share plunge is too great, overdone. He might add on even more weakness. Trades at 14x forward PE and pays a 3.9% dividend. It's a great company on sale. They have a long track record of making acquisitions.

COMMENT

Regarding the results of the U.S. election there should be less regulation which is pumping up financial service stocks as well as others. The fed rate cuts have engineered what looks like a perfect soft landing and this has been good for equity markets. Some of this has already been priced in with these surging markets. One of the market risks is that the stimulus package of the world's second largest economy, China, is not having a big impact. Earnings reports for big international companies have been affected by the weakness in China. However he thinks China's economy will get rolling again because China will keep on providing more stimulus measures. 
There has been a move away from large cap tech, the magnificent 7 for the most part, and the market spreading out to undervalued companies.

Unspecified

It is better now than before but it has lots of debt and negative free cash flow. It has survived over time but has always been somewhat levered and has performed poorly for a long time. Due to the low price it could be time to buy now but you have to be able to handle risk.

BUY

It is a pharma company trading at 5X earnings. It is buying back stock, as much as 5% and has a slew of new products.

BUY

The question was on his preference of this group of wealth management companies. He owns all three for different reasons. The possible lack of regulation under the new administration has already boosted them. They are in excellent financial shape and have good dividend growth. It is not an expensive sector.